PRMT5 and MAT2A inhibitors hold promise for the future treatment of these patients whether they present with or subsequently develop advanced disease and the evaluation in MTAP loss in this clinical setting as a route to novel therapies in NSCLC appears warranted. Here, MTAP is linked to non-small cell lung carcinoma.